Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease

Although fibrates were developed as lipid‐lowering drugs, their efficacy against liver dysfunction in patients with cholestatic liver diseases, such as primary biliary cholangitis, primary sclerosing cholangitis, and fatty liver disease, has also been reported. Although fibrates act on some peroxisome proliferator‐activated receptors (PPARs), pemafibrate is a novel selective PPAR‐α modulator. The present study aimed to evaluate the safety and efficacy of switching from bezafibrate to pemafibrate in patients with chronic liver disease.

[1]  A. Irisawa,et al.  Effects of pemafibrate on primary biliary cholangitis with dyslipidemia , 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  K. Dohmen,et al.  Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis. , 2021, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[3]  H. Takagi,et al.  Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score , 2021, JGH open : an open access journal of gastroenterology and hepatology.

[4]  A. Lefor,et al.  Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study , 2021, Clinical and experimental hepatology.

[5]  K. Lindor,et al.  Safety of fibrates in cholestatic liver diseases , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[6]  M. Moriguchi,et al.  Effect of pemafibrate on fatty acid levels and liver enzymes in non‐alcoholic fatty liver disease patients with dyslipidemia: A single‐arm, pilot study , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

[7]  H. Isomoto,et al.  Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease. , 2020, Yonago acta medica.

[8]  H. Aburatani,et al.  Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content , 2020, Scientific Reports.

[9]  S. Yamashita,et al.  Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases , 2020, Current Atherosclerosis Reports.

[10]  Naoyuki Fujimori,et al.  Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

[11]  C. Corpechot.  The Role of Fibrates in Primary Biliary Cholangitis , 2019, Current Hepatology Reports.

[12]  J. Boyer,et al.  Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[13]  A. Parés.  Primary biliary cholangitis. , 2018, Medicina clinica.

[14]  M. Unno,et al.  Clinical guidelines for primary sclerosing cholangitis 2017 , 2018, Journal of Gastroenterology.

[15]  V. de Lédinghen,et al.  A Placebo‐Controlled Trial of Bezafibrate in Primary Biliary Cholangitis , 2018, The New England journal of medicine.

[16]  G. Hirschfield,et al.  EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. , 2017, Journal of hepatology.

[17]  S. Yamashita,et al.  Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. , 2016, Atherosclerosis.

[18]  M. Kowgier,et al.  Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes , 2016, Alimentary pharmacology & therapeutics.

[19]  Jie Lu,et al.  Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis , 2015, Drug design, development and therapy.

[20]  J. Boyer,et al.  Fibrates and cholestasis , 2015, Hepatology.

[21]  J. Kuroda,et al.  Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor‐β1 in a cultured stellate cell line , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

[22]  J Auwerx,et al.  Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.

[23]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[24]  J. Cottet,et al.  [Hypocholesterolemizing effect of some disubstituted acetic acids]. , 1953, Comptes rendus hebdomadaires des seances de l'Academie des sciences.